Related references
Note: Only part of the references are listed.Non-driver gene mutation analysis in a large cohort of polycythemia vera and essential thrombocythemia
Soji Morishita et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2023)
JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation
Garima Pandey et al.
BLOOD CANCER JOURNAL (2022)
In utero origin of myelofibrosis presenting in adult monozygotic twins
Nikolaos Sousos et al.
NATURE MEDICINE (2022)
Circulating microbial content in myeloid malignancy patients is associated with disease subtypes and patient outcomes
Jakob Woerner et al.
NATURE COMMUNICATIONS (2022)
Comprehensive characterization of posttranscriptional impairment-related 3′-UTR mutations in 2413 whole genomes of cancer patients
Wenqing Wei et al.
NPJ GENOMIC MEDICINE (2022)
Fecal Microbial Community Composition in Myeloproliferative Neoplasm Patients Is Associated with an Inflammatory State
Andrew Oliver et al.
MICROBIOLOGY SPECTRUM (2022)
SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates
Giuseppe G. Loscocco et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Daniel A. Arber et al.
BLOOD (2022)
Molecular Pathogenesis of Myeloproliferative Neoplasms
Benjamin Rolles et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2022)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
Joseph D. Khoury et al.
LEUKEMIA (2022)
Inferring the initiation and development of myeloproliferative neoplasms
Gurvan Hermange et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)
The contribution of the intestinal microbiome to immune recovery after HCT
Alex E. Wolfe et al.
FRONTIERS IN IMMUNOLOGY (2022)
Discovery of INCA033989, a Monoclonal Antibody That Selectively Antagonizes Mutant Calreticulin Oncogenic Function in Myeloproliferative Neoplasms (MPNs)
Edimara Reis et al.
BLOOD (2022)
Transcriptome research identifies four hub genes related to primary myelofibrosis: a holistic research by weighted gene co-expression network analysis
Weihang Li et al.
Aging-US (2021)
Total Platelet Transcriptomics and Its Network Analysis by RNA-Seq and miRNA-Seq and PCA Application in Essential Thrombocythaemia
Kyung Chul Moon et al.
ACTA HAEMATOLOGICA (2021)
Single-Cell Multi-Omics Reveals the Genetic, Cellular and Molecular Landscape of TP53 Mutated Leukemic Transformation in MPN
Alba Rodriguez-Meira et al.
BLOOD (2021)
Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression
Stephan Bartels et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2021)
The Microenvironment in Myeloproliferative Neoplasms
Gajalakshmi Ramanathan et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2021)
Gut Microbiota Influence in Hematological Malignancies: From Genesis to Cure
Mireia Uribe-Herranz et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Myelodysplastic Syndromes and Metabolism
Ekaterina Balaian et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Polycythemia Vera and Essential Thrombocythemia Patients Exhibit Unique Serum Metabolic Profiles Compared to Healthy Individuals and Secondary Thrombocytosis Patients
Nuria Gomez-Cebrian et al.
CANCERS (2021)
Transcriptome profiling reveals target in primary myelofibrosis together with structural biology study on novel natural inhibitors regarding JAK2
Weihang Li et al.
Aging-US (2021)
Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms
Debra Van Egeren et al.
CELL STEM CELL (2021)
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis
Paola Guglielmelli et al.
BLOOD CANCER JOURNAL (2021)
Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signature
Samah Alimam et al.
BLOOD ADVANCES (2021)
PBX1-directed stem cell transcriptional program drives tumor progression in myeloproliferative neoplasm
Sharon Muggeo et al.
STEM CELL REPORTS (2021)
An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera
Monica Barone et al.
FRONTIERS IN ONCOLOGY (2021)
Mutations and thrombosis in essential thrombocythemia
Paola Guglielmelli et al.
BLOOD CANCER JOURNAL (2021)
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients
Giuseppe G. Loscocco et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Still a burning question: the interplay between inflammation and fibrosis in myeloproliferative neoplasms
Helene F. E. Gleitz et al.
CURRENT OPINION IN HEMATOLOGY (2021)
MAPK14 over-expression is a transcriptomic feature of polycythemia vera and correlates with adverse clinical outcomes
Chao Guo et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2021)
The Power of Extracellular Vesicles in Myeloproliferative Neoplasms: Crafting a Microenvironment That Matters
Lucia Catani et al.
CELLS (2021)
Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms
Zhu Shen et al.
CELL REPORTS MEDICINE (2021)
Multilevel defects in the hematopoietic niche in essential thrombocythemia
Ting Sun et al.
HAEMATOLOGICA (2020)
Platelets in myeloproliferative neoplasms have a distinct transcript signature in the presence of marrow fibrosis
Belinda B. Guo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions
Ruochen Jia et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2020)
Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera
Ayalew Tefferi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk
F. Ferrer-Marin et al.
LEUKEMIA (2020)
Genomic heterogeneity in myeloproliferative neoplasms and applications to clinical practice
Joe Lee et al.
BLOOD REVIEWS (2020)
Role of inflammation in the biology of myeloproliferative neoplasms
Steffen Koschmieder et al.
BLOOD REVIEWS (2020)
Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis
Catherine de Martel et al.
LANCET GLOBAL HEALTH (2020)
Microbes and Cancer: Friends or Faux?
Maria Manuel Azevedo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Single-Cell Analyses Reveal Megakaryocyte-Biased Hematopoiesis in Myelofibrosis and Identify Mutant Clone-Specific Targets
Bethan Psaila et al.
MOLECULAR CELL (2020)
Thrombotic Risk Detection in Patients with Polycythemia Vera: The Predictive Role of DNMT3A/TET2/ASXL1 Mutations
Adrian Segura-Diaz et al.
CANCERS (2020)
Genetic lesions disrupting calreticulin 3'-untranslated region in JAK2 mutation-negative polycythemia vera
Alberto Quattrocchi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Splicing Anomalies in Myeloproliferative Neoplasms: Paving the Way for New Therapeutic Venues
Marie Hautin et al.
CANCERS (2020)
Implications ofTP53allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Elsa Bernard et al.
NATURE MEDICINE (2020)
Low high-density lipoprotein and increased risk of several cancers: 2 population-based cohort studies including 116,728 individuals
Kasper Monsted Pedersen et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms
Ashok Kumar Jayavelu et al.
NATURE (2020)
Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms
Vasundhara Sharma et al.
FRONTIERS IN IMMUNOLOGY (2020)
Protein Carbonylation and Lipid Peroxidation in Hematological Malignancies
Alba Rodriguez-Garcia et al.
ANTIOXIDANTS (2020)
Bone marrow niches in haematological malignancies
Simon Mendez-Ferrer et al.
NATURE REVIEWS CANCER (2020)
miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2
Enrique Fuentes-Mattei et al.
JCI INSIGHT (2020)
State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019
Donal P. McLornan et al.
HAEMATOLOGICA (2019)
Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms
Fiorella Schischlik et al.
BLOOD (2019)
Gene expression profiling distinguishes prefibrotic from overtly fibrotic myeloproliferative neoplasms and identifies disease subsets with distinct inflammatory signatures
Waihay J. Wong et al.
PLOS ONE (2019)
Key Role of Inflammation in Myeloproliferative Neoplasms: Instigator of Disease Initiation, Progression. and Symptoms
Laura F. Mendez Luque et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2019)
Loss of EZH2 Reprograms BCAA Metabolism to Drive Leukemic Transformation
Zhimin Gu et al.
CANCER DISCOVERY (2019)
Metabolic Plasticity of Acute Myeloid Leukemia
Johanna Kreitz et al.
CELLS (2019)
JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms
Tata Nageswara Rao et al.
BLOOD (2019)
Metabolic dependencies and vulnerabilities in leukemia
Marissa Rashkovan et al.
GENES & DEVELOPMENT (2019)
Phosphoproteomic Landscaping Identifies Non-canonical cKIT Signaling in Polycythemia Vera Erythroid Progenitors
Giulia Federici et al.
FRONTIERS IN ONCOLOGY (2019)
Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study
Olivier Mansier et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Impact of hydroxycarbamide and interferon-α on red cell adhesion and membrane protein expression in polycythemia vera
Megane Brusson et al.
HAEMATOLOGICA (2018)
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis
Paola Guglielmelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Molecular Minimal Residual Disease in Acute Myeloid Leukemia
M. Jongen-Lavrencic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Impact of hydroxycarbamide and interferon-α on red cell adhesion and membrane protein expression in polycythemia vera
Megane Brusson et al.
HAEMATOLOGICA (2018)
Bone marrow specific loss of ABI1 induces myeloproliferative neoplasm with features resembling human myelofibrosis
Anna Chorzalska et al.
BLOOD (2018)
Role of TGF-beta 1/miR-382-5p/SOD2 axis in the induction of oxidative stress in CD34+cells from primary myelofibrosis
Chiara Rossi et al.
MOLECULAR ONCOLOGY (2018)
Circulating Extracellular Vesicles in Human Disease
Ravi Shah et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia
Yusuke Shiozawa et al.
NATURE COMMUNICATIONS (2018)
Classification and Personalized Prognosis in Myeloproliferative Neoplasms
J. Grinfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Smoking is associated with increased risk of myeloproliferative neoplasms: A general population-based cohort study
Kasper M. Pedersen et al.
CANCER MEDICINE (2018)
Targeting the CALR interactome in myeloproliferative neoplasms
Elodie Pronier et al.
JCI INSIGHT (2018)
Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms
Elisa Rumi et al.
BLOOD (2017)
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
William Vainchenker et al.
BLOOD (2017)
Enhanced calreticulin expression in red cells of polycythemia vera patients harboring the JAK2V617F mutation
Megane Brusson et al.
HAEMATOLOGICA (2017)
Genomics of Myeloproliferative Neoplasms
Katerina Zoi et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Proteomic analysis of JAK2V617F-induced changes identifies potential new combinatorial therapeutic approaches
S. Pearson et al.
LEUKEMIA (2017)
Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease
S. Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
CALR mutational status identifies different disease subtypes of es sential thrombocythemia showing distinct expression profiles
Roberta Zini et al.
BLOOD CANCER JOURNAL (2017)
Enhanced calreticulin expression in red cells of polycythemia vera patients harboring the JAK2V617F mutation
Megane Brusson et al.
HAEMATOLOGICA (2017)
Transcriptome Analysis of Monozygotic Twin Brothers with Childhood Primary Myelofibrosis
Nan Ding et al.
GENOMICS PROTEOMICS & BIOINFORMATICS (2017)
Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms
J-P Defour et al.
LEUKEMIA (2016)
Brain-Gut-Bone Marrow Axis: Implications for Hypertension and Related Therapeutics
Monica M. Santisteban et al.
CIRCULATION RESEARCH (2016)
miR-203 and miR-221 regulate SOCS1 and SOCS3 in essential thrombocythemia
A. Navarro et al.
BLOOD CANCER JOURNAL (2016)
Targeting glutamine metabolism in myeloproliferative neoplasms
Huichun Zhan et al.
BLOOD CELLS MOLECULES AND DISEASES (2015)
Osteogenic Potential of Mesenchymal Stromal Cells Contributes to Primary Myelofibrosis
Christophe Martinaud et al.
CANCER RESEARCH (2015)
Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study
Malin Hultcrantz et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
JAK2 Exon 14 Skipping in Patients with Primary Myelofibrosis: A Minor Splice Variant Modulated by the JAK2-V617F Allele Burden
Paolo Catarsi et al.
PLOS ONE (2015)
Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
Raajit Rampal et al.
BLOOD (2014)
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms
Pontus Lundberg et al.
BLOOD (2014)
Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in The Iowa Women's Health Study cohort
Alexis D. Leal et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients
A. Tefferi et al.
LEUKEMIA (2014)
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Siddhartha Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Transcriptomic and phospho-proteomic analyzes of erythroblasts expanded in vitro from normal donors and from patients with polycythemia vera
Todd Hricik et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
MicroRNAs in myeloproliferative neoplasms
Huichun Zhan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Proteomic analysis reveals heat shock protein 70 has a key role in polycythemia Vera
Miguel Gallardo et al.
MOLECULAR CANCER (2013)
Mutations and prognosis in primary myelofibrosis
A. M. Vannucchi et al.
LEUKEMIA (2013)
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
J. Nangalia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Cancer cell metabolism: implications for therapeutic targets
Miran Jang et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2013)
Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome
Su-Jiang Zhang et al.
BLOOD (2012)
Changes in advanced oxidation protein products, advanced glycation end products, and s-nitrosylated proteins, in patients affected by polycythemia vera and essential thrombocythemia
Caterina Musolino et al.
CLINICAL BIOCHEMISTRY (2012)
Patterns of Survival Among Patients With Myeloproliferative Neoplasms Diagnosed in Sweden From 1973 to 2008: A Population-Based Study
Malin Hultcrantz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity
M. M. Reddy et al.
LEUKEMIA (2012)
SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients
T. L. Lasho et al.
LEUKEMIA (2012)
EZH2 mutational status predicts poor survival in myelofibrosis
Paola Guglielmelli et al.
BLOOD (2011)
FLT3-Mediated p38-MAPK Activation Participates in the Control of Megakaryopoiesis in Primary Myelofibrosis
Christophe Desterke et al.
CANCER RESEARCH (2011)
Microbial Dysbiosis in Colorectal Cancer (CRC) Patients
Iradj Sobhani et al.
PLOS ONE (2011)
NF-κB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies
Jimmy L. Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis
Elaine M. Boyd et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Transcriptional Profiling of Polycythemia Vera Identifies Gene Expression Patterns Both Dependent and Independent from the Action of JAK2V617F
Windy Berkofsky-Fessler et al.
CLINICAL CANCER RESEARCH (2010)
Oxidative stress is increased in primary and post-polycythemia vera myelofibrosis
Claudia Vener et al.
EXPERIMENTAL HEMATOLOGY (2010)
JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms
Wanlong Ma et al.
PLOS ONE (2010)
Proteomic study of the impact of the JAK2-V617F mutation on the phenotype of essential thrombocythemia
Pascal Mossuz et al.
EXPERIMENTAL HEMATOLOGY (2008)
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
Linda M. Scott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Molecular profiling of CD34(+) cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1)
Paola Guglielmelli et al.
STEM CELLS (2007)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin
F Ding et al.
BLOOD (2004)
Nicotine induces human neutrophils to produce IL-8 through the generation of peroxynitrite and subsequent activation of NF-kappa B
S Iho et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2003)
Share Paper
